Immunovant Names Renee Barnett CFO

Immunovant, Inc. (IMVT), a clinical-stage biopharmaceutical company, on Wednesday, announced the appointment of Renee Barnett as its Chief Financial Officer, effective from October 4.

With two decades of experience in healthcare, Barnett began her career at Eli Lilly, where she developed expertise in strategic financial leadership across the drug development life cycle through to commercialization, both in the U.S. and in Europe.

During her tenure at Lilly, her roles included CFO of Lilly Austria and Switzerland as well as global lead for financial planning and analysis.

Recently, Barnett served in a variety of executive-leadership functions at AbleTo, Inc., a technology-enabled healthcare service provider focused on the virtual delivery of behavioral healthcare, the company said in a statement.

Barnett joins the company at a time when Immunovant prepares to initiate a pivotal trial in myasthenia gravis (MG) as well as reinitiate its programs in thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA).

For comments and feedback contact: editorial@rttnews.com

Follow RTT